A5080215451- Lung Cancer Treatments and Mutations
- Colorectal Cancer Treatments and Studies
- Lung Cancer Research Studies
- Hepatocellular Carcinoma Treatment and Prognosis
- Colorectal and Anal Carcinomas
- Gastric Cancer Management and Outcomes
- Cancer Genomics and Diagnostics
- Lung Cancer Diagnosis and Treatment
- Cancer Treatment and Pharmacology
- Genetic factors in colorectal cancer
- Pancreatic and Hepatic Oncology Research
- Neuroendocrine Tumor Research Advances
- Ovarian cancer diagnosis and treatment
- Cancer therapeutics and mechanisms
- Colorectal Cancer Surgical Treatments
- Renal cell carcinoma treatment
- Radiomics and Machine Learning in Medical Imaging
- Estrogen and related hormone effects
- Multiple and Secondary Primary Cancers
- Cancer-related Molecular Pathways
- Medical Imaging and Pathology Studies
- Gastrointestinal Tumor Research and Treatment
- Cholangiocarcinoma and Gallbladder Cancer Studies
- BRCA gene mutations in cancer
- HER2/EGFR in Cancer Research
Hospital de Cruces
2012-2025
Osakidetza
2006-2015
211 Background: Prostate cancer remains the most prevalent solid tumor in men and third leading cause of cancer-related mortality globally. Tumor aggressiveness poorer clinical outcomes are associated with certain germline variants. Current technological developments genetic testing have improved identification variants uncertain significance (VUS), adding complexity to challenging process decision-making. The aim this project was explore potential correlation between identified patients...
Metastatic melanoma is a lethal skin cancer and its incidence rising every year. It represents challenge for oncologist, as the current treatment options are non-curative in majority of cases; therefore, effort to find and/or develop novel compounds mandatory. Pemetrexed (Alimta®, MTA) multitarget antifolate that inhibits folate-dependent enzymes: thymidylate synthase, dihydrofolate reductase glycinamide ribonucleotide formyltransferase, required de novo synthesis nucleotides DNA...
Based on the mechanism of action, combining somatostatin analogues (SSAs) with mTOR inhibitors or antiangiogenic agents may provide synergistic effects for treatment patients neuroendocrine tumours (NETs). Herein, we investigate use these combinations in clinical practice. This retrospective cross-sectional analysis NETs treated SSA lanreotide and targeted therapies at 35 Spanish hospitals evaluated efficacy safety The data 159 133 was retrospectively collected. Of patients, a median age...
The biological roles of estrogen receptor 1 (ERS1), 2 (ERS2), and aromatase (CYP19A1) genes in the development non-small cell lung cancer (NSCLC) is unclear, as use their expression a prognostic factor. aim this study was to investigate value receptors mRNA expression, along with protein concentration, resected NSCLC patients. Tumor non-tumor tissue samples were analyzed for ERS1, ERS2 CYP19A1 by RT-PCR. Aromatase concentration measured an ELISA. A total 96 patients included. ERS1...
Although treatment options for cancer patients are increasing every year, the drug resistance problem remains very present. It is difficult to find a that acts equally on tumours of same histology as individual's genetic characteristics often determine response treatment. Furthermore, initially respond anti-tumour therapy able adapt and develop drug, while others do not. In addition, this usually implies development agents which cells have not been exposed, phenomenon called cross-resistance...
The optimal form of exercise for individuals with cancer has yet to be identified, but there is evidence that improves their quality life. aim this study assess the efficacy and efficiency an innovative physical programme, undergoing chemotherapy breast, gastrointestinal or non-small cell lung tumours, improving life, reducing level fatigue, enhancing functional capacity over time.We will conduct a clinical trial in 66 patients stage IV cancer, recruited by Department Oncology referral...
308 Background: Pancreatic and biliary tree ADC represent poor prognostic tumors. Gemcitabine is usually considered the first- line chemotherapy after that no standard treatment has been established. CAP OX have demonstrated some activity in metastatic (M1) locally advanced (LA) pancreatic cancer, combination of these drugs confers additional benefit as well. We conducted this study order to establish efficacy schedule on ADC. Methods: Pts with M1 or LA progression one previous were...
Aims and background Gemcitabine is an effective agent in pancreatic adenocarcinoma. Fixed-dose-rate gemcitabine has interesting biological clinical rationale, with successful results previous studies. We conducted a trial to confirm efficacy toxicity of fixed-dose-rate patients or biliary tree Methods Eligible locally advanced metastatic adenocarcinoma received at dose 1500 mg/m 2 rate 10 /min weekly for 3 weeks every 28 days. Efficacy measures were overall survival, response...
Gastrointestinal stromal tumors (GISTs) represent the most frequent mesenchymal tumor of gastrointestinal tract. Less than 5% them seem to be hereditary, being succinate dehydrogenase complex (SDHx) deficient disorders and neurofibromatosis type 1 more related inherited conditions. Wild (WT) KIT PDGFRα GISTs constitute a clue for hypothetical underlying germline condition.We present case 20 years old female diagnosed gastric WT GIST who developed hepatic metastases during her clinical...
e18031 Background: B in combination with platinum doublets followed by continuation maintenance prolongs survival and delays progression chemo-naïve pts advanced (nsNSCLC). P C is efficacious nsNSCLC as frontline treatment. This phase II study aims to evaluate the efficacy safety of B, plus nsNSCLC. Methods: Chemo-naïve unresectable stage IIIB or IV were treated (75 mg/m 2 ), (500 (7.5 mg/kg) on day 1 every 21 days up 6 cycles. Pts response stable disease (SD) received until unacceptable...
Colorectal cancer (CRC) is a highly prevalent disease in developed countries. Inherited Mendelian causes account for approximately 5% of CRC cases, with Lynch syndrome and familial adenomatous polyposis being the most forms. Scientific efforts are focused on discovery new candidate genes associated associations phenotypes well-established cancer-related genes. BRCA1-associated ring domain (BARD1) gene deleterious germline variants moderate increase relative risk breast cancer, but their...
e22182 Background: Current microarray technologies allow the analysis of thousands genes simultaneously. We analyze gene expression profile different samples from human colorectal carcinoma in relation with clinical stage at diagnosis. Methods: Thirty-one patients were included: 13 II (transmural invasion colonic wall without lymph node invasion), 10 III (regional invasion) and 8 IV diagnosis (metastatic). RNA was extracted fresh tumour samples, quantity quality assessed by...
Purpose: To evaluate the efficacy and safety of fixed-dose-rate infusions gemcitabine in combination with erlotinib for advanced pancreatic cancer. Methods/Patients: Patients locally (LAPC) or metastatic cancer (MPC) without previous treatment disease Eastern Cooperative Oncology Group performance status received 1500 mg/m2 150-minute (10 mg/m2/minute) on days 1, 8 15 4-week cycles combined 100 mg/day oral erlotinib. The primary endpoint was overall survival (OS). Results: Sixty-two...
18505 Background: Lung cancer is increasingly diagnosed in elderly patients and the first cause of death. Treatment this subset represents a challenge to medical oncologists. Methods: We retrospectively reviewed clinical characteristics, co-morbidity (Charlson Index), toxicity results all ≥ 65 years (y) old, advanced NSCLC. compared these with younger patients’. Results: From January-95 June-02, we treated 477 (pt), 176 years, 301 < y. Treatment: 177 pt, MIC (mitomycine + ifosfamide...
e11525 Background: Antiangiogenic therapies such as bevacizumab (BV), have proven to be effective in improving outcomes metastatic disease from several tumor types. For breast cancer (MBC), combinations of BV and established chemotherapy regimens potentially offer new, more efficacious treatments without the significant toxicity associated with combining multiple cytotoxic agents. Methods: This is a retrospective chart review that reflects Hospital Cruces experience combination patients MBC....
e13000 Background: Glioblastoma multiforme constitutes the most common and malignant form of primary brain tumor. Median survival for recurrent disease is 3-9 months. Combining bevacizumab with irinotecan represents an option treatment in GBM. Methods: We performed a retrospective review patients GBM treated (10 mg/kg) (340 mg/m 2 receiving enzyme-inducing antiepileptic drugs –EIAEDs- 125 not EIAEDs) every 14 days on 4-week cycle. Inclusion criteria: age ≥ 18, histology GBM, progression...
Background: Efficacy and safety data for cisplatin pemetrexed plus bevacizumabinnon squamousnon non-small cell lung cancer (NSCLC) are still limited. Nevertheless, either bevacizumab platinum doublet or is approved options first line therapy. Predictive factors needed. KRAS one of the most common oncogenic drivers in cancer. Its prognostic predictive value NSCLC under investigation. Patients methods: This trial evaluates addition 7.5 mg/kg to 75 mg/m2 500 as treatment stage IV non-squamous...
e19036 Background: Both pemetrexed-cisplatin and bevacizumab-based therapy are treatment options for patients with advanced non-squamous NSCLC. The objective of this study was to explore efficacy safety first-line plus bevacizumab followed by maintenance in a sample Spanish patients, also the K-Ras VEGF status. Methods: Patients (N = 31) previously untreated NSCLC were enrolled. PFS OS assessed Kaplan-Meier curves analyzed using log-rank test Cox proportional hazards model. K-RAS mutational...
Introduction: Bevacizumab combined with IFL (irinotecan, bolus 5-fluorouracil, and leucovorin) has been shown to improve outcomes for patients metastatic colorectal cancer (mCRC). However, infusional 5-fluorouracil-based combinations are now considered optimal in this setting. We analyzed the efficacy toxicity of FOLFIRI leucovorin)-bevacizumab an unselected cohort consecutive mCRC. Materials Methods: Patients unresectable mCRC received bevacizumab 5 mg/kg irinotecan 180 mg/m² on day 1,...